Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.

@article{Milenic2008CetuximabPE,
  title={Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.},
  author={Diane E. Milenic and K. J. Wong and Kwamena E. Baidoo and Geoffrey L. Ray and Kayhan Garmestani and Mark I. Williams and Martin W. Brechbiel},
  journal={Cancer biotherapy & radiopharmaceuticals},
  year={2008},
  volume={23 5},
  pages={619-31}
}
The monoclonal antibody, cetuximab, binds to epidermal growth-factor receptor and thus provides an opportunity to create both imaging and therapies that target this receptor. The potential of cetuximab as a radioimmunoconjugate, using the acyclic bifunctional chelator, CHX-A"-DTPA, was investigated. The pharmacokinetic behavior in the blood was determined in mice with and without tumors. Tumor targeting and scintigraphic imaging were evaluated in mice bearing xenografts of LS-174T (colorectal… CONTINUE READING

8 Figures & Tables

Connections & Topics

Mentioned Connections BETA
The monoclonal antibody , cetuximab , binds to epidermal growth - factor receptor and thus provides an opportunity to create both imaging and therapies that target this receptor .
The monoclonal antibody , cetuximab , binds to epidermal growth - factor receptor and thus provides an opportunity to create both imaging and therapies that target this receptor .
Cetuximab : preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications .
All Topics